Back to top
more

Avenue Therapeutics (ATXI)

(Delayed Data from NSDQ)

$4.51 USD

4.51
58,704

-0.27 (-5.65%)

Updated May 6, 2024 04:00 PM ET

After-Market: $4.52 +0.01 (0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ATXI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Avenue Therapeutics, Inc. [ATXI]

Reports for Purchase

Showing records 1 - 20 ( 41 total )

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

12/31/2021

Company Report

Pages: 5

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

11/29/2021

Daily Note

Pages: 3

Decision on IV Tramadol''s NDA Is Now Expected by March 17, 2022; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

11/17/2021

Company Report

Pages: 6

3Q21 Recap; Awaiting Details of AdCom to Potentially Define IV Tramadol''s Regulatory Path; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

11/05/2021

Daily Note

Pages: 3

Avenue Terminated SPMA With InvaGen After October 31 Deadline; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

10/25/2021

Daily Note

Pages: 3

New AdCom to Resolve Second FDRR; Just Days From Cipla''s October 31 SPMA Deadline; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ATXI

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

08/27/2021

Daily Note

Pages: 3

Avenue Needs Funding to Further Pursue FDRR Appeal and Potential IV Tramadol Approval; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

08/17/2021

Company Report

Pages: 6

2Q21 Recap: Formal Dispute Resolution Request Submitted; First Response Expected By August 26; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

07/16/2021

Daily Note

Pages: 3

Glimmer of Hope Remains for IV Tramadol As Formal Dispute Resolution Process to Begin in 3Q21; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

06/15/2021

Company Report

Pages: 5

Second CRL Cites Delayed and Unpredictable Onset of Analgesia; Removing PT and Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

05/18/2021

Company Report

Pages: 8

1Q21 Recap; Over a Month Past the PDUFA, Still Awaiting FDA Decision; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

04/01/2021

Company Report

Pages: 8

4Q20 Recap; We Continue to Expect IV Tramadol Approval By April 12 But Uncertain on InvaGen Takeout; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

03/01/2021

Daily Note

Pages: 3

IV Tramadol Gets Another Shot; New PDUFA April 12; InvaGen Takeout May Still Be in Play

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

02/16/2021

Daily Note

Pages: 3

NDA Resubmission As Expected But SPMA Completion Remains Uncertain; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

12/21/2020

Daily Note

Pages: 3

Peer-Reviewed Publications Affirm Tramadol''s Low Likelihood For Abuse; Maintain Neutral Ahead of NDA Resubmission

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

12/18/2020

Daily Note

Pages: 3

NDA Resubmission Expected in February 2021; Potential FDA Approval as Soon as April 2021; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

11/05/2020

Company Report

Pages: 8

3Q20 Recap: Awaiting FDA Meeting in 4Q20 to Delineate IV Tramadol''s Regulatory Path; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

10/12/2020

Company Report

Pages: 8

Could Anti-Opioid Political Pressure Be at Play in IV Tramadol CRL? Downgrade to Neutral on Unclear Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

08/14/2020

Company Report

Pages: 7

2Q20 Recap: We Expect IV Tramadol Approval by October 10 PDUFA Date to Advance InvaGen Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

06/08/2020

Daily Note

Pages: 4

IV Tramadol''s Safety, Efficacy and Abuse Liability Assessed in Three Peer-Reviewed Articles; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party